During the first half of the year we continued our focus on the further development of Dizlin’s potential treatments for late stage Parkinson’s disease. During the summer we completed an additional financing round from current shareholders which allows us to continue with the current prioritized activities. 

An update on these prioritized activities is as follows: 

The development of the Infudopa SubC™ pump, which has been identified as the single most important activity at the moment, is proceeding according to plan. We expect to have a working prototype at the end of September and a pump which can be used in clinical trials at year end.

A peer-reviewed article containing results from our completed IPO-001 study, which was previously announced, has been accepted to a highly regarded scientific journal. The article is already published in a short version (abstract) and will shortly be published in its entirety.  We look forward to communicating more once the article is published in its entirety. 

The work with Infudopa IntraV™ has intensified and given high priority in order to reach a registration in one or more countries in Europe as soon as possible. In parallel with this, the planning continues for the upcoming study which will form the basis for an approval for Infudopa IntraV™ in the USA (FDA).

We are also proceeding with the Pre-IND (Investigational New Drug) application for Infudopa SubC™ as well as hydrazine testing and a detailed market analysis for Infudopa IntraV™. The market analysis for Infudopa IntraV™ is expected to provide us with feedback from payers and physicians regarding pricing, product profile, product positioning and commercial opportunity.  

August 2022

Björn Velin
CEO, Dizlin Pharmaceuticals AB